What Gilead’s Big Hepatitis C Discounts Mean for Biosimilar Pricing
Drug Channels - February 5, 2015
This week, Gilead Sciences reported blockbuster 2014 results for its hepatitis C products Sovaldi and Harvoni. However, Wall Street freaked out when Gilead disclosed that its payer discounts are much larger than many people had assumed—more than 50% off list in some cases.
Another one bites the dust: FDA to revoke breakthrough status for BMS hep C med, too
BioPharma Dive - February 11, 2015
Bristol-Myers Squibb is joining Merck at the back of the HCV line as the FDA plans to revoke breakthrough designation for BMS' new daclatasvir-based hep C treatment.
Study: “This growing trend of diabetes cost is simply unsustainable”
AHIP Coverage - February 3, 2015
The cost of diabetes care has more than doubled in the past 20 years, mostly driven by the rising price of new drugs, concludes a study recently published in the Diabetes Care journal.
FDA approved more than 40 novel drugs in 2014
Drug Topics - February 2, 2015
The Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research approved 41 new molecular entities in 2014, including several for cancer, type 2 diabetes, hepatitis C, and other serious diseases.
Engineered insulin could offer better diabetes control
ScienceDaily - February 10, 2015
Engineers hope to improve treatment for diabetes patients with a new type of engineered insulin. In tests in mice, the researchers showed that their modified insulin can circulate in the bloodstream for at least 10 hours, and that it responds rapidly to changes in blood-sugar levels.
A Pill a Day? No Way, Survey Says
HealthDay News - February 3, 2015
One out of three adults would sooner face a shorter life span than take a daily pill to prevent heart disease, a new Internet survey found.
HRSA withdraws proposed 340B rule
Drug Topics - January 10, 2015
Observers predicted that the rule would address issues identified in a report issued by the U.S. Department of Health and Human Services (HHS) Inspector General, which cited, among other concerns, inconsistencies in how contract pharmacies determine whether a prescription is 340B-eligible when they dispense the drug on behalf of a covered entity.
Some ARB Drugs Are More Effective Than Others at Treating Heart Failure
Nova Southeastern University - February 3, 2015
Millions of people take angiotensin receptor blockers (ARBs) to help treat heart failure. But it turns out not all ARBs are created equally, according to one Nova Southeastern University (NSU) researcher’s findings.
Pharmacists part of innovative programs to reduce hospital readmissions
Drug Topics - February 3, 2015
Doing everything possible to ensure patients aren’t readmitted in the hospital shortly after discharge is not only in the best interest of patients, but it is in the financial best interests of hospitals.
Using Drugs to Discriminate — Adverse Selection in the Insurance Marketplace
The New England Journal of Medicine - January 29, 2015
Eliminating discrimination on the basis of preexisting conditions is one of the central features of the Affordable Care Act (ACA). Before the legislation was passed, insurers in the nongroup market regularly charged high premiums to people with chronic conditions or denied them coverage entirely.
Contact,
Jan Tankersley
Senior Vice President, Marketing & Sales
Pharmaceutical Strategies Group (PSG)
Office: 972-943-7141
Email: JTankersley@PSGConsults.com
PSGNewsletter@PSGConsults.com
www.PSGConsults.com
 |
 |
 |